The year chemotherapy finally gets some respect!

Nature Reviews Urology

Volumn 12, Issue 2, 2015, Pages 71-72

  Saad, Fred ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ALKALINE PHOSPHATASE; ANDROGEN RECEPTOR; DOCETAXEL; ENZALUTAMIDE; PROSTATE SPECIFIC ANTIGEN; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; PHENYLTHIOHYDANTOIN; TAXOID;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; LONG TERM SURVIVAL; MALE; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SHORT SURVEY; STATISTICAL SIGNIFICANCE; VISCERAL METASTASIS; ANALOGS AND DERIVATIVES; PROCEDURES; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

ANDROSTENES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; PHENYLTHIOHYDANTOIN; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TAXOIDS;

EID: 85028248926     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2014.362     Document Type: Short Survey

References (9)

1. de Bono, J. S., Logothetis, C. J. & Molina, A. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995-2005 (2011).
2. Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187-1197 (2012).
3. Beer, T. M. et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371, 424-433 (2014).
4. Ryan, C. J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138-148 (2013).
5. Rathkopf, D. E. et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2014.02.056.
6. Ryan, C. J. et al. Final overall survival (OS) analysis of COU-AA-302, a randomized phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy [abstract 7530]. Ann. Oncol. 25 (Suppl. 4), iv255-iv279 (2014).
7. Antonarakis, E. S. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371, 1028-1038 (2014).
8. Sweeney, C. et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial [abstract]. J. Clin. Oncol. 32 (Suppl.), LBA2 (2014).
9. Bill-Axelson, A. et al. Radical prostatectomy or watchful waiting in early prostate cancer. N. Engl. J. Med. 370, 932-942 (2014).